Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi...
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven...
Sandoz, the generics and biosimilars arm of Swiss drugmaker Novartis, has signed a Memorandum of Understanding to build a biologics production plant in Lendava, Slovenia...
Genentech, the US biotech arm of Swiss pharma giant Roche, is building a new small-batch biologics manufacturing facility at its Oceanside campus in California, USA...
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...
US scientific equipment manufacturer Thermo Fisher Scientific and China-based CDMO Innoforce have formed a joint venture to own and operate a new pharma services facility...
25.02.2019
- Catalent appointed Kay Schmidt as senior vice president, Technical Operations. In this new role, Schmidt will report to Alessandro Maselli, who earlier this month was appointed as...
